ArticleActa endocrinologica (Bucharest, Romania : 2005)
INCREASED SERUM LEVEL OF FGF21 IN GESTATIONAL DIABETES MELLITUS.
Article in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Circulating miR-326 and miR-532-3p: novel biomarkers for early gestational diabetes mellitus detection with high diagnostic accuracy.Journal of endocrinological investigation · 2026Article
- Overlap of Gestational Diabetes Mellitus and Pre-eclampsia: A Scoping Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Efficiency of afamin and fibroblast growth factor 21 for early prediction of gestational diabetes mellitus.Scientific reports · 2026Article
- Association of Serum Sortilin and Insulin Resistance in Patients with Gestational Diabetes Mellitus.EJIFCC · 2025Article
- Article
- Elevated Serum Tsukushi Levels and Their Association with Glycolipid Metabolism in Gestational Diabetes Mellitus Patients.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Predictive Utility of Biochemical Markers for the Diagnosis and Prognosis of Gestational Diabetes Mellitus.International journal of molecular sciences · 2024Review
- The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review.International journal of molecular sciences · 2023Review
- Progress in Research on Biomarkers of Gestational Diabetes Mellitus and Preeclampsia.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Fibroblast Growth Factor 21 in Gestational Diabetes Mellitus and Type 2 Diabetes Mellitus.Journal of diabetes research · 2023Article
- The relationship between serum adipokine fibroblast growth factor-21 and gestational diabetes mellitus.Journal of diabetes investigation · 2022Article
- Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases.Oxidative medicine and cellular longevity · 2022Review
- Early markers of gestational diabetes mellitus: what we know and which way forward?Biochemia medica · 2021Review
- FGF21 Serum Levels in the Early Second Trimester Are Positively Correlated With the Risk of Subsequent Gestational Diabetes Mellitus: A Propensity-Matched Nested Case-Control Study.Frontiers in endocrinology · 2021Article
- Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases.Cardiovascular diabetology · 2019Review
- GESTATIONAL DIABETES MELLITUS AND THE DEVELOPMENT OF CLEFT LIP / PALATE IN NEWBORNS.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGestational diabetes mellitus (GDM) is a common endocrine complication in pregnancy. There are few risk factors that clearly correlate with GDM. Fibroblast growth factor 21 (FGF21) is a metabolic hormone that can regulate glucose metabolism. It has been recognized that serum levels of FGF21 are significantly increased in diabetes and insulin resistance states. The objective of this study was to determine the serum FGF21 levels in women with GDM compared with non-GDM women and its correlation with insulin resistance.
methodsThirty GDM patients and 60 healthy pregnant controls that matched for maternal and gestational age were selected. Women with previous history of GDM, hypertension, polycystic ovary syndrome, renal or liver failure and drug consumption with effects on glucose or insulin levels were excluded. FGF21 was determined and correlated with biochemical parameters of glucose metabolism and insulin resistance.
resultsFGF21 concentration was significantly higher in GDM (264.5±196.2 ng/L) as compared with control groups (59.1±36.5ng/L). Correlation of FGF21 with insulin resistance was not significant. A cut-off 82.07 ng/L of FGF21 had sensitivity of 100% and specificity of 85% for prediction of GDM.
conclusionFGF21 is increased in GDM and it is independent of insulin resistance. We suggest that FGF21 resistance could be directly involved in pathophysiology of GDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.